Marta Llorens-Agost

Marta Llorens-Agost

Auto-generated profile, based on publicly available information

Marta Llorens-Agost

Radiation Biology and DNA Repair, Technical University of Darmstadt, Darmstadt, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MLMarta Llorens-Agost
Marta Llorens-Agost
MEMichael Ensminger
Michael Ensminger
HLHang Phuong Le
Hang Phuong Le
AGAnugrah Gawai
Anugrah Gawai
JLJie Liu
Jie Liu
MLMarkus Löbrich
Markus Löbrich

2 November 2021 in Molecular & Cellular Oncology
Verified
Journal Article
Closed access
MLMarta Llorens-Agost
Marta Llorens-Agost
MEMichael Ensminger
Michael Ensminger
HLHang Phuong Le
Hang Phuong Le
WHWolf-Dietrich Heyer
Wolf-Dietrich Heyer
MLMarkus Löbrich
Markus Löbrich
How cells deal with DNA breaks during mitosis is not well understood. While canonical non-homologous end-joining predominates in interphase, it is inhibited in mitosis to avoid telomere fusions. DNA polymerase θ mediated end-joining appears to be repressed in interphase, but promotes break repair in mitosis. The nature and induction time of breaks might determine their fate during mitosis.

27 October 2021 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MLMarta Llorens-Agost
Marta Llorens-Agost
MEMichael Ensminger
Michael Ensminger
HLHang Phuong Le
Hang Phuong Le
AGAnugrah Gawai
Anugrah Gawai
JLJie Liu
Jie Liu
MLMarkus Löbrich
Markus Löbrich

28 March 2022 in BIOspektrum
Verified
Journal Article
Open access
PDF file
MEMichael Ensminger
Michael Ensminger
MLMarta Llorens-Agost
Marta Llorens-Agost
MLMarkus Löbrich
Markus Löbrich
Mutations in BRCA1 or BRCA2 are associated with breast, ovarian and other cancers. Cells with these mutations are defective in homologous recombination (HR), one of two main processes to repair DNA double-strand breaks (DSBs). Survival of these cells strongly relies on the usage of alternative repair pathways, such as POLθ-mediated end-joining (TMEJ). Thus, targeting TMEJ could be a promising new strategy for the therapy of BRCA1- and BRCA2-mutant tumours.